Baricitinib is a rheumatoid arthritis drug that is being used for the treatment of Covid-19 positive in combination with Remdesivir. (Representative image/AFP)
HYDERABAD: Pharma player Natco Pharma Limited on Monday said it has received emergency use authorisation approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from the Central Drugs Standard Control Organization (CDSCO).
Natco said it will be seeking a compulsory license for the drug, which is sold under the brand name Olumiant by Eli Lilly & Co, based on emergency use in light of the grave and serious public health emergency across India due to the Covid-19 pandemic.
Natco Pharma seeks approval for Molnupiravir capsules for Covid-19 treatment
PTI
Hyderabad |
Updated on
American pharma major Merck along with Ridgeback Bio therapeutics has developed the drug
Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients.
American pharma major Merck along with Ridgeback Bio therapeutics has developed Molnupiravir(MK-4482).
According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, it said.